Balchem Corporation research snapshot
BCPC AI stock analysis currently reads Balchem Corporation as a high-margin specialty chemical and nutrition ingredient supplier with durable customer relationships and consistent earnings. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $162.15, market capitalization was about $5.21 billion, and the main question was whether steady earnings growth and the companys encapsulation and choline market positions can justify a roughly 33x TTM earnings multiple. This is informational research and not investment advice.
Current price
$162.15
Market cap
$5.21 billion
AI score
65 / 100
Rating
High-quality niche business, premium valuation
Trend status
Below 52-week high, range-bound since mid-2025
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Balchem supplies specialty nutritional ingredients and encapsulation technology to food, pharma, animal feed, and industrial customers, with high gross margins and a 59-year operating history. | High |
| Moat | The moat comes from proprietary encapsulation technology, scale in choline production, long-term customer relationships, regulatory qualifications, and application expertise that is hard to replicate quickly. | Medium-high |
| Management | Leadership has demonstrated consistent capital allocation with steady margins, moderate debt use, and periodic bolt-on acquisitions. Long tenure provides stability but raises succession risk. | Medium |
| Financial trend | Revenue has grown at a mid-single-digit to low-double-digit pace over recent years. TTM revenue was about $1.06 billion and TTM net income about $158 million, with net margins near 15%. | High |
| Valuation | The stock traded near 33x TTM earnings and roughly 39x TTM free cash flow at the cutoff, a premium to many specialty chemical peers but potentially justified by consistent margins and market position. | Medium |
| Technical trend | BCPC traded in a range between about $140 and $184 over the past year, below its 52-week high of $183.90, with mixed momentum signals near the middle of the range. | Medium |
| Risk level | Key risks are raw material cost volatility, customer concentration, acquisition integration, agricultural end-market cycles, and valuation multiple compression for a mid-cap ingredient supplier. | Medium-high |
| AI confidence | Moderate-high confidence for the business map, financial filings, market cap math, and major risk categories. Lower confidence for future growth rates and M&A outcomes. | Moderate-high data confidence |
| Investment certainty | Medium-low certainty. Balchem is a quality business, but the premium valuation and limited near-term catalysts leave a narrow margin of safety. | Medium-low |
BCPC AI stock forecast
The BCPC AI stock forecast uses scenario ranges around the $162.15 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained margin performance, successful bolt-on acquisitions, and market share gains in human nutrition and animal health. The base case assumes steady compounding at historical growth rates. The bearish case assumes margin compression, acquisition missteps, or valuation normalization for a mid-cap ingredient supplier.
$240 to $274
More likely if Balchem sustains 10-12% annual EPS growth through organic expansion and accretive M&A, maintains gross margins above 35%, and the market assigns a forward PE near 35-40x reflecting consistent performance and niche market leadership.
$180 to $215
More likely if Balchem continues 6-8% annual EPS growth with steady margins, and the stock trades near its historical forward PE range of 28-33x.
$100 to $140
More likely if raw material costs compress margins, a major customer is lost, M&A integration problems emerge, or the market resets specialty chemical valuations toward a low-20s earnings multiple.
BCPC AI technical analysis
BCPC AI technical analysis starts from the $162.15 July 10 close used for this July 12 static page. Public technical sources showed the stock below its 52-week high of $183.90 but above its 52-week low of $139.17, with mixed momentum in a range-bound pattern. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $162.15 | Latest verified close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $150 to $155 | Support planning zone near prior reaction lows from early 2026. |
| Secondary support | $139 to $142 | The 52-week low area. A sustained break below this level would weaken the long-term technical picture. |
| Near resistance | $170 to $175 | Resistance zone near the upper end of the recent trading range. |
| Major resistance | $183 to $184 | The 52-week high. A breakout above this level with volume would signal a new uptrend. |
| 50-day moving average | Approximately $158 to $162 | Google Finance technical data showed BCPC trading near its 50-day MA around the cutoff. |
| 200-day moving average | Approximately $155 to $160 | BCPC was trading near or slightly above its 200-day MA, providing a neutral-to-slightly-bullish long-term signal. |
| Momentum | RSI near 50, mixed oscillators | RSI was near the neutral 50 level, indicating no clear overbought or oversold signal. |
| Volume | About 250,000 shares | Average daily volume is approximately 262,000 shares. Low volume can amplify price moves. |
| Volatility | Moderate, beta 0.81 | The stock has below-market volatility, with a beta of 0.81, making it less reactive to broad market moves. |
| Invalidation | Close below $150, then $139 | A close below $150 would weaken the near-term range-bound setup. A break below the 52-week low would challenge the technical trend. |
BCPC AI trading strategy
The BCPC AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Look for BCPC to hold above the 50-day and 200-day moving averages and break above $170 with improving volume before treating an uptrend as confirmed.
A failed breakout or daily close below $150 should reduce confidence in the setup.
If BCPC pulls back toward $150 to $155 without a fundamental thesis break, compare price stabilization with upcoming quarterly earnings, margin trends, and M&A signals.
Do not average down solely because Balchem has a long operating history. Define maximum loss and review valuation first.
Track quarterly revenue growth, gross margin trends, segment performance (Human Nutrition, Animal Nutrition, Specialty Products), acquisition integration, and insider trading activity.
Lower the rating if organic growth slows while the stock still trades at a premium multiple relative to specialty chemical peers.
Investment research summary
Balchem supplies encapsulated nutrients, choline, and specialty ingredients that customers integrate into food, feed, pharmaceutical, and industrial products. Customers pay for formulation reliability, regulatory compliance, and application expertise that is hard to replicate internally.
The moat combines proprietary encapsulation technology, a leading position in choline production, long-standing customer relationships built over decades, regulatory and food-safety certifications, and application know-how that creates switching costs. The scale advantage in choline and microencapsulation is significant but not unassailable.
The thesis can fail if raw material price spikes compress margins, a key customer or supplier relationship is disrupted, an acquisition destroys value, encapsulation technology is replaced by a cheaper alternative, or the premium multiple normalizes as investor interest shifts away from mid-cap ingredient suppliers.
Management has demonstrated consistent execution with steady margin improvement and moderate debt. The leadership team has long tenure at the company, which supports institutional knowledge but raises key-person risk. Capital allocation has focused on bolt-on acquisitions and organic investment rather than large transformative deals.
Balchem benefits from long-term trends in human nutrition awareness, animal feed efficiency, and specialty food preservation. The shift toward clean-label ingredients and functional foods supports demand for Balchem encapsulation solutions. However, end-market growth is gradual rather than explosive, and the company is exposed to agricultural and commodity cycles.
At roughly 33x TTM earnings and about 39x TTM free cash flow, the stock trades at a premium to many specialty chemical peers. The market is pricing in consistent mid-single-digit to low-double-digit growth and sustained margins. The three-scenario model suggests a base-case target of $180-215 over three years, implying modest upside from the $162.15 cutoff with limited downside protection.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BCPC price | $162.15 close on July 10, 2026 | Google Finance quote snapshot | July 12, 2026 |
| Market capitalization | $5.21 billion, verified as $162.15 x 32.13M shares | financial_rigor.py market cap verification and Google Finance | July 12, 2026 |
| TTM revenue (last 4 quarters) | Approximately $1.06 billion (Q2 2025 $255.47M, Q3 2025 $267.56M, Q4 2025 $263.62M, Q1 2026 $270.71M) | Google Finance income statement quarterly data | July 12, 2026 |
| TTM net income (last 4 quarters) | Approximately $158.07 million (Q2 2025 $38.28M, Q3 2025 $40.29M, Q4 2025 $39.22M, Q1 2026 $40.28M) | Google Finance income statement quarterly data | July 12, 2026 |
| TTM EPS | $4.87 | Google Finance key statistics | July 12, 2026 |
| P/E ratio (TTM) | 33.30x, verified as $162.15 / $4.87 | Google Finance and financial_rigor.py valuation verification | July 12, 2026 |
| 52-week range | $139.17 to $183.90 | Google Finance | July 12, 2026 |
| Shares outstanding | 32.13 million | Google Finance | July 12, 2026 |
| Beta | 0.81 | Google Finance | July 12, 2026 |
| Dividend yield | 0.59% ($0.24 quarterly) | Google Finance | July 12, 2026 |
| Q1 2026 revenue and net income | Revenue $270.71M, net income $40.28M, EPS $1.33 | Google Finance income statement | July 12, 2026 |
| Analyst consensus | 2 Buy ratings, average price target $212 (range $190-$234) | Google Finance analyst ratings | July 12, 2026 |
| Valuation math | 33.30x TTM PE, ~38.6x TTM P/FCF, 2.59% FCF yield from financial_rigor.py | financial_rigor.py valuation verification and Google Finance data | July 12, 2026 |
This BCPC AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
